POPULARITY
10 episodes with neuroendocrine tumors
7 episodes with neuroendocrine tumors
4 episodes with neuroendocrine tumors
5 episodes with neuroendocrine tumors
5 episodes with neuroendocrine tumors
7 episodes with neuroendocrine tumors
2 episodes with neuroendocrine tumors
2 episodes with neuroendocrine tumors
2 episodes with neuroendocrine tumors
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
In this episode, surgical oncologist Dr. Seth Concors of Emory's Winship Cancer Institute discusses the role of the surgical oncologist within the multidisciplinary care team for neuroendocrine cancer. We explore what surgical oncologists do, why NET-specific experience matters, how surgical decisions are made, and what patients can expect during a surgical consultation. The conversation highlights coordination across care teams, common patient concerns, and the importance of informed decision-making and second opinions, offering practical guidance for patients and caregivers navigating surgical care in neuroendocrine cancer.TOP TEN QUESTIONS Understanding the Surgeon's Role1. What is a surgical oncologist, and what kind of training does that involve? How is a surgical oncologist similar to—or different from—other types of surgeons? Patients may hear the term “HPB surgeon.” What does that mean, and how can a patient tell if their surgeon is an HPB surgeon? 2. When a patient is looking for a surgeon, how can they find someone who is the “right fit” for them? How can patients know whether a surgeon has experience with the specific operation they may need—such as a Whipple procedure, liver surgery, or lung surgery? How important is it for a surgeon to be familiar with neuroendocrine tumors specifically?3. What should patients expect at their first appointment with a surgical oncologist? What key information are you usually trying to communicate during that first visit? What questions do you encourage patients and caregivers to ask their surgeon?4. How often should patients expect to see their surgical oncologist, and at what points in their care?Surgical Decision-Making5. How do you determine whether someone is a surgical candidate? What is the typical goal of surgery for neuroendocrine tumors?6. If someone is not a surgical candidate initially, does that mean surgery is off the table forever? Are there treatments that can help make surgery possible in the future? How many NET surgeries can someone safely have over their lifetime? Can major surgeries—such as extensive liver resections—affect eligibility for future treatment options?Multidisciplinary and Coordinated Care7. How do surgical oncologists work within a multidisciplinary care team for NET patients? How do you collaborate with providers at different institutions, such as a local oncologist working with a NET specialty center?8. What is your perspective on second opinions, specifically for neuroendocrine cancer?9. Many patients worry about carcinoid crisis during surgery. How do you address and manage those concerns?Preparing for Surgery10. Patients often ask how they can best prepare—physically and emotionally—for surgery. What guidance do you typically offer?BONUS: What research is currently being done involving neuroendocrine surgery?ABOUT THE SPEAKERSeth Concors, MD, is an academic surgical oncologist at Emory University and the Winship Cancer Institute, where he serves as Associate Program Director for both the General Surgery Residency and the Complex General Surgical Oncology Fellowship, and Director of the Surgical Oncology Research Fellowship. He leads Emory's Peritoneal Surface Malignancy and Neuroendocrine Tumor surgical programs, with clinical and research interests focused on gastrointestinal neuroendocrine tumors, cytoreductive surgery/HIPEC, and survivorship outcomes. Dr. Concors is actively involved in national surgical societies, including SSO, SSAT, NANETS, ACS, and ECOG-ACRIN, and his work emphasizes multidisciplinary collaboration, prospective outcomes research, and surgical education. He is committed to advancing patient-centered cancer care while mentoring the next generatioFor more information, visit NCF.net.
To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro 00:01:54 - Formula for Infants 00:22:22 - Neuroendocrine Tumor (NET) 00:46:26 - Constipation - Inflammation - Chronic Kidney Disease 01:14:21- Constant Pain -Swelling - Hernia 00:01:54 - Formula for Infants Do you have a recipe for a healthy formula? 00:22:22 - Neuroendocrine Tumors (NETs) The main tumors are on the small intestines. 00:46:26 - Constipation - Inflammation - Chronic Kidney Disease One night I was rushed to the emergency room for excruciating pain on the left side of my abdomen. 01:14:21- Constant Pain -Swelling - Hernia He only feels okay while he's asleep.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
This week's episode will be focusing on Neuroendocrine Tumors (NET). We will go over all the important details regarding the heterogeneous group of NETs, diagnosis, work-up, treatment, and focus mostly on gastro-entero-pancreatic NETs.
What considerations drive your decision between bland embolization, TACE, and radioembolization in managing neuroendocrine tumors? In this BackTable episode, Dr. Daniel DePietro, interventional radiologist at the University of Pennsylvania joins host Dr. Kavi Krishnasamy for an in-depth discussion on the interventional management of neuroendocrine tumors. --- SYNPOSIS The physicians start by discussing the intricacies of primary and metastatic neuroendocrine tumors, focusing on how treatment decisions are shaped by factors such as symptom burden, extent of disease requiring debulking, and symptom progression despite systemic therapy. Dr. DePietro shares insights from his clinical experience and emphasizes the critical role of interdisciplinary collaboration in optimizing patient outcomes. Dr. DePietro then shares his approach to using Y90 radioembolization in patients with biliary contraindications to TACE or bland embolization—such as those with prior Whipple surgery, sphincterotomy, or biliary stents—where the risk of hepatic abscess with ischemia-based therapies is higher. He also notes that patients who derive less than a year of benefit from prior TACE or bland embolization may be good candidates for radioembolization. The conversation also covers the role of thermal ablation in select patients with solitary lesions, and also touches on several key trials, including the ongoing CapTemY90 study. --- 00:00 - Introduction02:09 - Specialization in Neuroendocrine Tumors06:32 - Patient Selection and Treatment Criteria10:40 - Grading and Treatment of Neuroendocrine Tumors16:09 - Systemic Therapy Options22:22 - Rebiopsy and Its Importance28:01 - Technical Aspects of Local Regional Therapies39:14 - Radioembolization: When and How43:33 - Segmentectomy and Multimodal Approaches45:22 - CapTemY90 Trial and Promising Results49:52 - Hormone Release During Local Regional Therapies53:12 - Combining Radioembolization with PRT56:12 - Thermal Ablation in Neuroendocrine Tumor Patients58:06 - Follow-Up Imaging and Tumor Markers01:02:40 - Updates from Nanets Conference01:05:08 - Collaborating Across Specialties01:07:56 - Managing High Tumor Burden Patients01:13:59 - Treating Carcinoid Heart Disease01:19:37 - Closing Remarks and Acknowledgments --- RESOURCES NETTER-1 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1607427 REMINET Trialhttps://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.TPS4148 CapTemY90 Trialhttps://www.clinicaltrials.gov/study/NCT04339036#contacts-and-locations
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon, Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it's diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing.In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.)TOP TEN QUESTIONS What is carcinoid syndrome? Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative, but someone can still have carcinoid syndrome?Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome?For those who have carcinoid syndrome, what additional tests should they have?Why should carcinoid syndrome be treated? What are the possible issues if it is not treated?How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment?Can carcinoid syndrome be prevented or detected early? Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome, such as age, weight or other diseases? You recently published a study discussing the possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug, and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings?ABOUT DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa. His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs.For more information, visit NCF.net/podcast/49For more information, visit NCF.net.
Neuroendocrine Tumors Explained: Symptoms, Treatments, and Breakthroughs with guest Dr. Pamela Kunz November 17, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Neuroendocrine Tumors Explained: Symptoms, Treatments, and Breakthroughs with guest Dr. Pamela Kunz November 17, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic. Join us as we explore: • The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67. • The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions. • Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments. • Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin. • Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!
In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:The clinical implications of using DLL3 as a therapeutic targetThe impact of emerging DLL3-targeted therapies on evolving treatment paradigmsHow to incorporate DLL3-based treatments into clinical practicePresenters:Daniel Morgensztern, MDProfessor of MedicineClinical Director of Thoracic OncologyWashington University School of MedicineSt Louis, MissouriJonathan Strosberg, MDProfessorDepartment of GI OncologyMoffitt Cancer Center and Research InstituteTampa, FloridaContent based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Link to full program: https://bit.ly/4mjNPfy
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs. In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration. Don't miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration
Neuroendocrine tumors are rare and can present with a confusing range of symptoms, which leads to frequent misattribution. Jay Bart Rose, M.D., explains how they're also complex to treat, often requiring multiple modalities based on tumor location and hormone activity. He discusses surgery, systemic therapies, and PRRT, a targeted treatment that uses the same receptor pathway as specialized imaging. Learn how UAB's multidisciplinary neuroendocrine tumor clinic brings specialists together for long-term management.
Join the Behind the Knife Surgical Oncology Team as we discuss the two key studies investigating optimal management strategies of neuroendocrine tumors of the small bowel. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. - Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode we review two important papers that discuss optimal management strategies of neuroendocrine tumors (NET) of the small bowel. The first paper by Singh and colleagues discusses the NETTER-2 trial investigating the role of radioligand therapy for NET as a first-line treatment. The second article by Maxwell et all challenges surgical dogma regarding optimal debulking cutoffs for debulking of NET. Links to Papers Referenced in this Episode: 1. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203. https://pubmed.ncbi.nlm.nih.gov/38851203/ 2. Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9. PMID: 26454679; PMCID: PMC4688152. https://pubmed.ncbi.nlm.nih.gov/26454679/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic neuroendocrine tumors, and also palliative interventions. Dr. Perez and Del Rivero share how to use this guideline in concert with the systemic therapy for tumor control in metastatic well-differentiated GEP-NETs guideline, and hope for the future for the treatment of gastroenteropancreatic neuroendocrine tumors. Read the full guideline, “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Transcript This guideline, clinical tools, and resources are available on ASCO.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in JCO Oncology Practice. Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Kim Perez from Dana-Farber Cancer Institute and Dr. Jaydira Del Rivero from the Center for Cancer Research at the National Cancer Institute, co-chairs on “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Thank you for being here today, Dr. Del Rivero and Dr. Perez. Dr. Kim Perez: Thank you. Dr. Jaydira Del Rivero: Thank you so much for the invitation. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Perez and Dr. Del Rivero, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to jump into the content here, first Dr. Del Rivero, could you provide an overview of the scope and purpose of this guideline? Dr. Jaydira Del Rivero: Yeah. Thank you so much. Well, first, we really wanted to thank ASCO for allowing us to develop these guidelines for the management of gastroenteropancreatic neuroendocrine tumors. I do want to mention that there is also another set of guidelines that I was very fortunate also to co-chair with Dr. Perez on the systemic management of gastroenteropancreatic neuroendocrine tumors. But when discussing these guidelines as well as with the different panelists, experts in this type of disease, we also realized that the management of these tumors are quite complex, not only from the management of the disease progression, but at the same time, management of the symptoms related to the hormone excess. And because of that, we like to thank ASCO for allowing us to then not only have a discussion on the systemic management of these tumors, but at the same time develop recommendations for the symptoms related to the different hormones that these neuroendocrine tumors may produce. These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms related to hormone excess, such as carcinoid syndrome, carcinoid heart disease, how to manage carcinoid crisis, as well as the different symptoms and how to manage the functional pancreatic neuroendocrine tumors and as well as provide recommendations in the different treatments for these tumor types, not only from the systemic management but also from the surgical management as well as for liver-directed therapy options and the different aspects in terms of the palliative care of these patients to improve not only the symptoms related to the hormone excess caused by these tumors, but as well as to improve the quality of life. Brittany Harvey: Absolutely. And I appreciate that overview. And yes, we'll link the guideline on the Systemic Therapy for Tumor Control for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors in the show notes for our listeners so that they can refer to that companion guideline as well. So then you just described the several different categories of recommendations that this guideline covers on symptom management. So, Dr. Perez, I'd like to start reviewing some of those key recommendations of that guideline. So, starting with what are the key recommendations for carcinoid syndrome and carcinoid heart disease? Dr. Kim Perez: Thank you Brittany. Yeah, I also want to thank ASCO for inviting us to do this podcast today. Just to start, I think these guidelines will really add to what's available in the literature to provide a kind of a quick look for the community provider to manage carcinoid-related symptoms. I think the highlights that I would point out are we've all been using somatostatin analogs for the last few decades to manage symptoms, but with the newer treatments that are now available, we tried to highlight what does the literature support in regards to PRRT, what does the literature support in regards to using systemic therapy for disease management, but also the benefits that you will get from a symptom management perspective using other modalities. I think the highlight really is it's a multidisciplinary approach. We are now considering surgery and embolization or interventional radiology as a critical piece. And I think the third that I'd highlight is the fact that sometimes we get too focused on carcinoid syndrome and the symptoms will actually, may result from other things. And the highlight in the algorithms that we've provided is what other things cause carcinoid-related diarrhea. And let's not forget about that because we will find ourselves treating and patients getting very frustrated with persistence of symptoms when in actuality, we should be treating something else that is causing a very similar symptom. For carcinoid heart disease, I think there are more and more guidelines that are now available to provide guidance there, but I think the major advances are that we should be utilizing heart assessment with echocardiogram with lab values such as BMP. But also critical to this is consulting with our cardiology colleagues and making sure that we're identifying heart related issues that are resulting from hormone excess sooner than later because interventions on the earlier side can really make a significant impact on quality of life and associated comorbidities and mortality. Brittany Harvey: Thank you for reviewing those key points for both carcinoid syndrome and carcinoid heart disease symptom management. So then the next set of recommendations. Dr. Del Rivero, what are the key highlights for symptom management of functioning pancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: Yes, it's very important to recognize the symptoms related to hormone excess due to pancreas neuroendocrine tumors. Up to 10% of pancreas neuroendocrine tumors may produce different hormones. Among those hormones can be insulin, gastrin, glucagon, somatostatin. So it's important to know and understand that based on what a neuroendocrine tumor is, they may produce different types of hormones. The importance of these guidelines is to also recognize some of these symptoms and how to address that, because it's not necessarily in these tumor types besides the management of metastatic disease, and know the different options that we recommend for metastatic disease from the systemic therapy, such as chemotherapy or targeted therapies or PRRT. It's important to recognize the symptoms because based on the symptoms we may recommend a different approach. That's something that is important to acknowledge and recognize. Moreover, in certain functional pancreas neuroendocrine tumors, as Dr. Perez mentioned, is a multidisciplinary approach. And it's important to also discuss these different cases with your endocrinologist. You may need to have an experienced endocrinologist to manage, for example, the excess of insulin. And also discuss your cases with a surgeon and interventional radiologist because some of these approaches can certainly improve the symptoms related to hormone excess. I understand that sometimes medical oncologists in the communities may not have access to the multidisciplinary approach or have the different teams that can manage these tumors, and that's the reason why with these guidelines we wanted to establish the understanding of different symptoms associated with the hormone excess to these neuroendocrine tumors as well as how to manage this. For example, in the case of insulinoma, I think for the medical oncologist it is important to know that the everolimus is an option to be used for these tumors, not only to manage tumor progressions related to this tumor type at the same time, because everolimus as a side effect causes hyperglycemia, that can also improve some of the symptoms related to the excess of insulin besides the somatostatin agonist. I think these recommendations will allow the medical oncologist to recognize the symptoms and based on what the symptoms cause, then you can have a different approach that could be added to the systemic therapies options as well. Brittany Harvey: Yes, beyond systemic therapy, it's important to be recognizing symptoms to provide an individualized approach for every single patient. So then, following that overview of symptom management for functioning pancreatic neuroendocrine tumors, Dr. Perez, what is recommended regarding palliative interventions for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, great question. So I think what's unique to neuroendocrine tumors is that the palliative approach really mirrors what we would be doing for symptom management. Some of these patients are living a very long time with carcinoid related symptoms. And so the approach that we take for the carcinoid symptom control is going to mirror the palliative piece of it. I think for those who develop a burden of disease related symptoms, I think it mirrors what we do across the board for all cancer-related complications. And so I think what we attempted to highlight here and included one of our colleagues who focuses specifically on the field of palliative care and neuroendocrine tumors, was to never really lose sight of what we've been doing to care for symptom management throughout the patient's journey and to always rereview the etiology of the symptoms, ensure that we don't focus solely on carcinoid-related issues, but also the symptom management that we would apply to all patients with cancer-related burden symptoms. Brittany Harvey: Definitely. I think that's a helpful approach to consider when thinking about how to manage these palliative interventions as well. So then Dr. Del Rivero, what should clinicians know as they implement these symptom management recommendations? Dr. Jaydira Del Rivero: Yes, thank you so much for that question. As we have discussed in the last 10 or 15 minutes, we have discussed the different approaches on the management of gastroenteropancreatic neuroendocrine tumors. Clinicians, I think it's important to know that neuroendocrine tumors is a quite complex disease because we're not only addressing the management of tumor growth, but we're also addressing the management of the symptoms related to hormone excess and the complexity associated with that. When medical oncologists or clinicians implement these recommendations it's to understand what symptoms these tumors may cause related to the hormone excess but at the same time, how do we approach those symptoms? As Dr. Perez said that I think is very important is to recognize the different types of diarrhea. It doesn't mean that if the patient has worsening diarrhea, it doesn't mean that this is related to disease progression. So it's important to recognize so that way you can address that, because the type of diarrheas can be related because of the lanreotide or somatostatin agonist, it could be because of the prior surgery. I think it's important to recognize those in order to address the symptom. And the same with the gastroenteropancreatic neuroendocrine tumors. It's important to know what hormones they produce because there are different measurements that may be added to the systemic management of these tumors. I think that there are two aspects here, and that's the reason why these guidelines were implemented in the sense that not only we're going to manage disease progression of these tumors, or how do we manage the metastatic disease of these tumors, but at the same time, how do we manage the symptoms related to the hormone excess and the different complications. Moreover, I think, as we discussed earlier, we need to manage these tumors in a multidisciplinary approach. And something very important is not like one size fits all, because the treatment recommendations, it will depend on different characteristics in terms of the tumor presentations. And hormone excess is one of the important aspects to recognize so that way we can implement these recommendations that will definitely help the quality of life of these patients. Brittany Harvey: Absolutely. And using these guidelines in concert with the systemic therapy guidelines is key. And then beyond this impact for clinicians that Dr. Del Rivero has just outlined, Dr. Perez, what does this new guideline mean for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, I think that's an important highlight of this guideline. It really gives patients a voice. I think it recognizes the fact that these symptoms can go unmanaged or mismanaged or just missed, and patients commonly will come in feeling very frustrated and feeling very ill. And I think it will provide them a means to open up a conversation with their providers and say, “Hey, this is what I'm experiencing. Let's talk about what's available. How does this apply to me?” And I think that can be very empowering. I think it's really hard nowadays with so many sources and resources online and patients are really left wondering what are the bullet points that they should be bringing to their clinician appointments? And I think that these guidelines provide them a good framework for those discussions. Brittany Harvey: Yes, bringing these discussion points for patients is very important to be able to have those resources. And we have some patient resources and information available on the website for this guideline and we can link that in the show notes for listeners. So then you've both touched on the importance of this guideline for improving quality of life and we continue to see advancements in this field. So Dr. Del Rivera, what are the outstanding questions regarding symptom management and tumor control for gastroenteropancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: I have to say whenever somebody asks me that question, the word that I will say is I feel hopeful, because more than 10 years ago we didn't have that many options for gastroenteropancreatic neuroendocrine tumors. And it has been in the last decade or so that there has been more developments in the management of these tumors as well as the understanding of the symptoms related to these tumors. But that said, yes, we do need more therapies for gastroenteropancreatic neuroendocrine tumors. Of the treatment options that we have, we all know in the field that even though we have disease control by using the different options for the systemic management of gastroenteropancreatic neuroendocrine tumors, we need options where we can achieve an objective response, especially for these tumor types. But there is a significant volume of disease and we see a lot of these patients with gastroenteropancreatic neuroendocrine tumors. And now where the field is going is to make some of these therapies more effective, to develop more therapies as well. For example, immunotherapies, a different type of immunotherapy understand the tumor immune microenvironment of these tumors in order to develop therapies as well. From the antibody drug conjugates, I think that's a new way to also address or treat these tumor types, understanding about the different markers found on these tumors that way they can be addressed in different ways. Now with the development of new therapies, I think that's something that can help us as well not only have disease control and as well as having an objective response, but having a better objective response can certainly also help with the symptoms related to hormone excess too. In terms of other therapies, I think some of the issues that we encounter are like the refractory carcinoid diarrhea and how do we manage this. We do have therapies that can help us control the diarrhea in the refractory settings, such as telotristat. Telotristat is one of the newer medications that can help us control the refractory diarrhea. But that said, despite this, that we still encounter situations where it's sometimes difficult to control. I think in those situations it will be good to understand more about the biology of these tumors as well and how we manage. If there is a different time or how do we implement these options. I think there is so much to learn. But that said, I feel we're in hopeful times. We're understanding more about these tumors so that way we can help us develop better therapies not only to have control of the tumor growth as well having control of the symptoms. And it's the same with the pancreas neuroendocrine tumors in the metastatic setting. Sometimes it may be difficult to control this hormone excess. But understanding these and having therapies that can achieve more of an objective response, I think that will definitely help us more and manage these patients. But one aspect I want to mention, and Dr. Perez also mentioned as well, the fact that we have these guidelines that help us understand about the different symptoms related to hormone excess and how to address it, I think is very important because having symptoms related to hormone excess can be detrimental to the quality of life on patients with neuroendocrine tumors that may necessarily be related to disease progression and having this information is so important. And I'm hopeful for the different therapies. There's different clinical trials ongoing for neuroendocrine tumors and especially in the field of PRRT. And a lot of more information will come with the different alpha-PRRT and combination therapy. So more information to come in the next couple of years. So this is, in my opinion, hopeful times for this field. Brittany Harvey: It's great to hear that you're hopeful for all the developments in this field and we'll look forward to the development and discovery of new therapies and further research and then, hopefully incorporate those updates into guidelines in the future. So I want to thank you both so much for your work to develop these guidelines and thank you for your time today. Dr. Del Rivero and Dr. Perez. Dr. Jaydira Del Rivero: Thank you so much for having us. Dr. Kim Perez: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Featuring perspectives from Dr Simron Singh and Dr Jonathan Strosberg, including the following topics: Introduction (0:00) Initial Therapy for Advanced Neuroendocrine Tumors (NETs) — Dr Singh (6:48) Management of Progressive Advanced NETs — Dr Strosberg (28:50) CME information and select publications
Clinical investigators discuss available data guiding the management of neuroendocrine tumors. CME information and select publications here.
Clinical investigators discuss available data guiding the management of neuroendocrine tumors. CME information and select publications here.
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD? Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. MEET DR. JEROME ZACKSDr. Jerome Zacks is a Cardiologist/Carcinoid Heart Disease Specialist; retired since December of 2021; but remain active as Associate Clinical Professor of Medicine at the Icahn Medical School at Mount Sinai in New York City and founding member of the Center for Carcinoid and Neuroendocrine Tumors at the Icahn Medical School at Mount Sinai; founder of the Carcinoid Heart Center; formerly on the Medical Advisory Board of the Carcinoid Cancer Foundation; currently head the Electrocardiography course for the 4th Year Medical Student elective at the Mt. Sinai Medical Center which has resulted in an international reputation among students seeking Cardiology training in the United States. He has expertise in matters of health care Insurance Carriers' theft of funds from the Medicare program, has studied patterns of abuse in the Medicaid program and has extensive knowledge of pharmaceutical company abusive practices. Dr. Zacks continues to devote time to the care of patients with Carcinoid Heart Disease. He has served as a member of the Guidelines Committees of the European Neuroendocrine Tumor Society (ENETS) and of the North American Neuroendocrine Tumor Society (NANETS). He developed a new approach to compression stockings for patients with leg edema; he was granted a patent for this innovation. He has authored two national petitions urging Congress to mandate that any health care professional who uses one's license, in making decisions which influence a patient's care, be held to the SAME STANDARD OF CARE as the patient's treating professional. (These two petitions were blocked by Senator Cory Booker.) In his role as patients' physician, he has attempted to remove barriers of communication. His business card includes his personal mobile phone number as well as his email address and website information; He encourages patients to phone for immediate answers to urgent matters. Along with his wife, Yelena - an RN- they have devoted their professional lives to patients with heart disease from rare Neuroendocrine tumors. They have mentored 5 children, and are now learning from them and their 6 grandchildren have provided the real fuel and excitement for their lives.For more information, visit https://www.ncf.net/podcast/43For more information, visit LACNETS.org.
New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.
Did you know that lung neuroendocrine tumors (NETs) are often misdiagnosed as lung cancer due to overlapping imaging and histological features? Credit available for this activity expires: 3/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002284?ecd=bdc_podcast_libsyn_mscpedu
Dr. Rafael Amado, President, Head of Global Research and Development at Zai Lab, highlights the renewed interest in antibody-drug conjugates (ADCs) with advancements in linker technology and payload delivery, leading to improved therapeutic windows and reduced side effects. The Zai Lab lead ADC ZL-1310 has shown promising results in small cell lung cancer and the ability to cross the blood-brain barrier to treat brain metastases, a common complication in small cell lung cancer. Combining ADCs with immunotherapy can potentially enhance the immune response. Rafael elaborates, "ADCs have undergone a bit of a renaissance. In the past, traditional ADCs had many drawbacks. They had what's called a narrow therapeutic window. So the dose that was effective was very close to the dose that was toxic. This was due to many factors. The construction of the antibodies and the chemotherapy, which we call payload, wasn't liberated in the right compartment. Either the tumor microenvironment or the antibody was not well internalized and didn't go into the cancer cell." "There are now new generations of antibody-drug conjugates, and ZL-1310 is one of them. It uses a technology called TMALIN. The advantage of this is that the linker is quite specific and the antibody internalizes, it can release the payload, which is a different chemotherapy, than a classic ADC. Also, it can be digested in the tumor microenvironment, and the chemotherapy can penetrate cells that don't have the target just by influx into the cell. So that's called the bystander effect." #ZaiLaboratory #innovation #Cancer #ADC #Antibodydrug #Biotech #ClinicalTrials #DrugDevelopment #LifeSciences #Healthcare zailaboratory.com Download the transcript here
Dr. Rafael Amado, President, Head of Global Research and Development at Zai Lab, highlights the renewed interest in antibody-drug conjugates (ADCs) with advancements in linker technology and payload delivery, leading to improved therapeutic windows and reduced side effects. The Zai Lab lead ADC ZL-1310 has shown promising results in small cell lung cancer and the ability to cross the blood-brain barrier to treat brain metastases, a common complication in small cell lung cancer. Combining ADCs with immunotherapy can potentially enhance the immune response. Rafael elaborates, "ADCs have undergone a bit of a renaissance. In the past, traditional ADCs had many drawbacks. They had what's called a narrow therapeutic window. So the dose that was effective was very close to the dose that was toxic. This was due to many factors. The construction of the antibodies and the chemotherapy, which we call payload, wasn't liberated in the right compartment. Either the tumor microenvironment or the antibody was not well internalized and didn't go into the cancer cell." "There are now new generations of antibody-drug conjugates, and ZL-1310 is one of them. It uses a technology called TMALIN. The advantage of this is that the linker is quite specific and the antibody internalizes, it can release the payload, which is a different chemotherapy, than a classic ADC. Also, it can be digested in the tumor microenvironment, and the chemotherapy can penetrate cells that don't have the target just by influx into the cell. So that's called the bystander effect." #ZaiLaboratory #innovation #Cancer #ADC #Antibodydrug #Biotech #ClinicalTrials #DrugDevelopment #LifeSciences #Healthcare zailaboratory.com Listen to the podcast here
Join the Behind the Knife Surgical Oncology Team as we discuss the presentation, work-up, and management of neuroendocrine tumors of the small bowel. Learning Objectives: In this episode, we review the basics of neuroendocrine (NE) tumors of the small bowel, including how to evaluate patients with presenting symptoms consistent with NE tumors, initial work-up, staging, and management. We discuss key concepts including DOTATATE scans and medical therapies high yield for direct patient care and board exams. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Links to Paper Referenced in this Episode: Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709; PMCID: PMC5895095. https://pubmed.ncbi.nlm.nih.gov/28076709/ ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Neuroendocrine tumors have a multitude of different names, including carcinoid disease, carcinoid syndrome neuroendocrine tumor, and neuroendocrine neoplasia. Join Chris Curry as he learns about these 'zebra' tumors, and why they can be so difficult to diagnose .
HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Carl Gay, MD, MD Anderson, Misty Shields, MD, Ph.D., Indiana University Simon Comprehensive Cancer Center. Hildy shares her experience of losing a friend who was diagnosed with neuroendocrine tumors of the gastrointestinal system. Knowing that neuroendocrine cells are present in the lungs prompted Hildy to wonder if lung … Continue reading Size Matters! Small Cell Neuroendocrine Tumors Pack A Mighty Wallop →
In this episode of the Oncology Brothers podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Pamela Kunz, a world-renowned medical oncologist from the Yale Cancer Center, to discuss the complex landscape of neuroendocrine tumors (NETs). Join us as we explore: • The classification of neuroendocrine tumors based on grade, histological features, and the significance of KI-67. • The role of imaging modalities, including Gallium PET-CT and its importance in evaluating disease extent. • Treatment strategies for localized versus metastatic NETs, including the use of somatostatin analogs and the nuances of observation versus intervention. • Insights into the latest treatment options, including lutetium dotatate, Capecitabine-Temozolomide, and the anticipated approval of Cabozantinib. • The potential role of NGS testing and the challenges of combining chemotherapy with immunotherapy in high-grade neuroendocrine tumors. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of neuroendocrine tumors. Don't forget to like, subscribe, and check out our other episodes for more discussions on current standard of care treatment options, conference highlights, and new drug approvals. We look forward to seeing you at GI ASCO in January 2025! #OncologyBrothers #NeuroendocrineTumors #CancerCare #MedicalOncology #Podcast #NETs Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:The diagnosis and typical presenting symptoms of GEP-NETsFindings from recent key phase III studies including NETTER-2 and CABINETRecommendations for treatment sequencingNotable clinical pearls regarding GEP-NET therapiesCurrent guidelines for GEP-NET care and monitoringPresenters:Thor R. Halfdanarson, MDConsultant, Division of Medical OncologyProfessor of OncologyAssociate Professor of MedicineMayo Clinic Comprehensive Cancer CenterChair, Hepato-Pancreatico-Biliary Disease GroupRochester, MinnesotaJonathan StrosbergProfessor, GI OncologyChair, Neuroendocrine Tumor DivisionMoffitt Cancer Center and Research InstituteTampa, FloridaLink to full program: https://bit.ly/3Y0JWBa
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 1: First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) — Simron Singh, MD, MPH CME information and select publications
Featuring perspectives from Dr Pamela Kunz and Dr Simron Singh, including the following topics: Introduction (0:00) Overview (4:04) Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (NETs) (27:07) Multitarget Tyrosine Kinase Inhibitors for the Treatment of NETs (39:37) Other New Advances in the Management of NETs (50:29) CME information and select publications
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD CME information and select publications
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/Neuroendocrine).
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
Advances in the Care of Neuroendocrine Tumors (NETs) with guest Pamela Kunz September 15, 2024 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Advances in the Care of Neuroendocrine Tumors (NETs) with guest Pamela Kunz September 15, 2024 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
© 2020-2026 Ivy Podcast Discovery LLC
